Empagliflozin interacts with a defined set of drug classes, and is contraindicated in type 1 diabetes and recurrent genital infections. Screening for these before the first dose prevents almost all serious events.
Interaction classes to screen
| Class | Concern | Action |
|---|---|---|
| Metabolic inhibitors | Raised plasma levels and exaggerated effect | Reduce dose or space administration |
| Metabolic inducers | Reduced exposure and treatment failure | Review response and adjust |
| Same-target agents | Additive pharmacology | Avoid duplicate therapy |
| Agents affecting the same organ system | genital mycotic infection, volume depletion, rare ketoacidosis | Monitor and document |
Key takeaways
- Screen every new prescription against the patient's full medicine list.
- Common reactions, genital mycotic infection, volume depletion, rare ketoacidosis, are amplified by interacting drugs.
- Document the interaction check in the dispensing record.
- Re-screen whenever another long-term medicine is added.
Monitoring in practice
Most interaction risk is manageable with a scheduled review after the onset window of glucosuria within 24 hours, HbA1c effect over 12 weeks and one further check at steady state. Patients on multiple chronic medicines benefit from an annual structured medication review.
Empagliflozin at a glance
| Attribute | Detail |
|---|---|
| Drug class | SGLT2 inhibitor |
| Common brand | Jardiance |
| Licensed use | type 2 diabetes, heart failure and CKD |
| Available strengths | 10 mg, 25 mg |
| Dosage form | film-coated tablet |
| Typical onset | glucosuria within 24 hours, HbA1c effect over 12 weeks |
| Duration / dosing interval | 24-hour dosing |
| Storage | below 30 °C |
